1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Anesthesiology
  6. NPI Profile
  7. Prescriptions 1427445253

JOHN EMIL AKHNOUKH M.D.
Prescription History 1427445253
Anesthesiology - Pain Medicine in New York, NY

NPI Status: Active since April 20, 2015

Contact Information

800 2ND AVE RM 802
NEW YORK, NY
ZIP 10017
Phone: (212) 865-2670

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOHN EMIL AKHNOUKH M.D., an active Pain Medicine specialist practicing in New York, NY. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 101 documented patient claims. Among these therapy options, the most frequently utilized medication is Tizanidine Hcl, which accounts for 39 claims alone.

Medication Index

C
G
M
T
No matching medications currently found on file.

Cyclobenzaprine Hcl

Generic Formulation: Cyclobenzaprine HclSpecialty: Pain Management
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.0
Days Supply 584
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills37.1
Peer Average Days Supply949
Conservative Utilization

This provider writes prescriptions for this formulation 40.6% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $782.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.17

State Avg Cost Per Claim

$15.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Cyclobenzaprine is used short-term to treat muscle spasms. It is usually used along with rest and physical therapy. It works by helping to relax the muscles. This medication is not recommended for use in older adults because they may be at greater risk for side effects while using this drug. Ask the doctor or pharmacist for details.

Gabapentin

Generic Formulation: GabapentinSpecialty: Pain Management
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 370
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills113.9
Peer Average Days Supply3,301
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $179.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.80

State Avg Cost Per Claim

$17.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Meloxicam

Generic Formulation: MeloxicamSpecialty: Pain Management
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 510
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills66.8
Peer Average Days Supply1,938
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.8% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $96.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.41

State Avg Cost Per Claim

$5.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Pain Management
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 90
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply271
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $138.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.20

State Avg Cost Per Claim

$11.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Tizanidine Hcl

Generic Formulation: Tizanidine HclSpecialty: Pain Management
Provider Metrics Summary
Total Claims 39
30-Day Fills 41.0
Days Supply 1,206
NY State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills46.3
Peer Average Days Supply1,243
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $610.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.66

State Avg Cost Per Claim

$16.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury). It works by helping to relax the muscles.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JOHN EMIL AKHNOUKH M.D. provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pain Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.